Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin and Hepatic Fat Content in Healthy Volunteers
NCT02329405Phase 4Completed
- Sponsor
- University of Oulu
- Start
- Dec 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rifampicin in non-alcoholic fatty liver disease (NAFLD), sponsored by University of Oulu. Primary endpoint: Hepatic fat fraction at 8 days. Started Dec 2014; status: completed.
02
Drugs
rifampicin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02329405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02329405.